Yeah I just though Shire would want US rights since by the time Genzyme's exclusivity runs out they'ld be pretty far behind (I doubt a lot of patients switch) so a new mechanism would be better.
I am curious how Shire would place these with their ERT as my understanding is they are not meant to be used in a complimentary fashion.
Wonder if someone at Shire is really after Genzyme. What will this is be like 4-5 therapies competing directly against them?
I think genisi pointed out that enrollment for the Gaucher drug was slow.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.